<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699840</url>
  </required_header>
  <id_info>
    <org_study_id>MTA92</org_study_id>
    <secondary_id>U1111-1174-4339</secondary_id>
    <nct_id>NCT02699840</nct_id>
  </id_info>
  <brief_title>Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation</brief_title>
  <official_title>Observational Study of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Menactra® Administered in Individuals 2 Through 55 Years Old Under Standard Health Care Practice in the Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to generate local data on the safety of Menactra® in individuals 2
      to 55 years of age in the Russian Federation.

      Primary Objective:

        -  To describe the safety profile after 1 dose of Menactra® administered in individuals
           2-55 years of age under standard health care practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be enrolled after receipt of one dose of Menactra® during a routine health
      care visit. They will be monitored for safety throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting solicited injection site and systemic reactions after a single dose of Menactra® vaccine</measure>
    <time_frame>Day 0 to Day 7 post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema and Swelling, Solicited systemic: Fever (Temperature), Headache, Malaise and Myalgia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting unsolicited adverse events and serious adverse events after a single dose of Menactra® vaccine</measure>
    <time_frame>Day 0 to Day 28 post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Menactra Study Group 1</arm_group_label>
    <description>Participant aged 2 through 11 years at vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra Study Group 2</arm_group_label>
    <description>Participant aged 12 through 17 years at vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menactra Study Group 3</arm_group_label>
    <description>Participant aged 18 through 55 years at vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>No vaccine will be provided as part of this study</description>
    <arm_group_label>Menactra Study Group 1</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>No vaccine will be provided as part of this study</description>
    <arm_group_label>Menactra Study Group 2</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>No vaccine will be provided as part of this study</description>
    <arm_group_label>Menactra Study Group 3</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged 2 to 55 years will be enrolled after receipt of one dose of Menactra®
        during a routine health care visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2 through 55 years on the day of enrollment &quot;2 through 55 years&quot; means from the
             day of the 2nd birthday to the day before the 56th birthday

          -  For adults (18-55 years old) Informed consent form has been signed and dated by the
             participant.

          -  For minors: Informed consent form has been signed and dated by the parent. In
             addition, in accordance with the Institution Ethics Committee/Institution Review Board
             requirements and as appropriate for the age of the participant:

          -  participants aged 14 to 17 years are required to sign and date the informed consent
             form,

          -  participants aged 10 to 13 years are required to sign and date the assent form,

          -  for participants under 10 years, consent may be asked orally according to
             participant's age and ability for understanding

          -  Receipt of one dose of Menactra® on the day of inclusion and prior to enrollment into
             the study, in routine practice according to the approved local product insert.

        Exclusion Criteria:

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the
             enrollment) or planned participation during the present study period in a clinical
             study investigating a vaccine, drug, medical device, or medical procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcal Meningitis</keyword>
  <keyword>Meningococcal Infections</keyword>
  <keyword>Menactra®</keyword>
  <keyword>Meningococcal Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi&quot;.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

